Human subjects research with prisoners: putting the ethical question in context
By Osagie K. Obasogie and Keramet A. Reiter,
Bioethics
| 12. 16. 2010
[Commentary]
We write in response to the conversation initiated in Volume 24.1 of Bioethics, which focused on the role of prisoners in biomedical and behavioral research. As interdisciplinary legal scholars who have researched the history, ethics, and current practices of prison research in the United States, we write to encourage further dialogue about the Institute of Medicine's (IOM) recommendations to reform current standards for prisoners' participation as human subjects. Specifically, we challenge three critical assumptions, which underlie several articles in the Bioethics special issue.
First, we challenge the idea that a risk-benefit assessment applied to prisoner participants in research is too restrictive.1 On the contrary, we argue that it is too permissive. The IOM's risk-benefit proposal – the most significant of its five main recommendations – is designed to relax current standards that categorically restrict prisoners' participation as human subjects to four narrow situations that directly benefit prisoners.2 Current policies were implemented in response to substantial abuses directly connected to prisoners' vulnerability and deplorable prison conditions; a 1976 Commission concluded that widespread research in prisons should not be...
Related Articles
By Rachel Hall, The Guardian | 11.20.2025
Couples are needlessly going through IVF because male infertility is under-researched, with the NHS too often failing to diagnose treatable causes, leading experts have said.
Poor understanding among GPs and a lack of specialists and NHS testing means male infertility...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...